Insmed Gestione

Gestione criteri di controllo 2/4

Insmed Il CEO è Will Lewis, nominato in Sep2012, e ha un mandato di 12.17 anni. la retribuzione annua totale è $ 10.41M, composta da 7.5% di stipendio e 92.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.25% delle azioni della società, per un valore di € 29.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 10.5 anni.

Informazioni chiave

Will Lewis

Amministratore delegato

US$10.4m

Compenso totale

Percentuale dello stipendio del CEO	7.5%
Mandato del CEO	12.2yrs
Proprietà del CEO	0.3%
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	10.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Will Lewis rispetto agli utili di Insmed?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$864m
Jun 30 2024	n/a	n/a	-US$803m
Mar 31 2024	n/a	n/a	-US$747m
Dec 31 2023	US$10m	US$780k	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Compensazione vs Mercato: La retribuzione totale di Will ($USD 10.41M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.00M ).

Compensazione vs guadagni: La retribuzione di Will è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Will Lewis (55 yo)

12.2yrs

Mandato

US$10,411,260

Compensazione

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
William Lewis	President	12.2yrs	US$10.41m	0.25% € 29.0m
Sara Bonstein	Chief Financial Officer	4.8yrs	US$4.56m	0.010% € 1.2m
Roger Adsett	Chief Operating Officer	5yrs	US$4.01m	0.036% € 4.1m
John Wise	Chief Commercial Officer	5yrs	US$3.89m	0.029% € 3.3m
Martina Flammer	Chief Medical Officer	4.9yrs	US$4.22m	0.0071% € 820.3k
Brian Kaspar	Chief Scientific Officer	no data	Nessun dato	Nessun dato
Eleanor Barisser	Associate Director of Investor Relations	no data	Nessun dato	Nessun dato
Michael Smith	Chief Legal Officer & Corporate Secretary	3.3yrs	Nessun dato	0.038% € 4.4m
Mandy Fahey	Executive Director of Corporate Communications	no data	Nessun dato	Nessun dato
S. Schaeffer	Chief People Strategy Officer	11.8yrs	US$2.66m	0.019% € 2.2m
Eugene Sullivan	Chief Product Strategy Officer	7.5yrs	US$1.69m	Nessun dato
Neil Hughes	GM & Head of Europe	5.4yrs	Nessun dato	Nessun dato

5.0yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di IM8N è esperto e expertise (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
William Lewis	President	12.2yrs	US$10.41m	0.25% € 29.0m
David W. McGirr	Independent Director	11.1yrs	US$320.00k	0.048% € 5.5m
Melvin Sharoky	Independent Director	23.5yrs	US$312.50k	0.18% € 21.0m
Alfred Altomari	Independent Director	12.3yrs	US$320.00k	0.031% € 3.6m
David Brennan	Lead Independent Director	10.5yrs	US$345.00k	0.061% € 7.0m
Clarissa Desjardins	Independent Director	5yrs	US$315.00k	0.027% € 3.2m
Elizabeth Anderson	Independent Director	6yrs	US$310.00k	0.031% € 3.6m
Leo Lee	Independent Director	6.5yrs	US$317.50k	0.062% € 7.2m
Carol Schafer	Independent Director	4.6yrs	US$315.00k	0.025% € 2.9m

10.5yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di IM8N è composto da personale esperto e esperto (durata media dell'incarico 10.5 anni).

Insmed Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Chief People Strategy Officer recently sold €628k worth of stock

Insufficient new directors

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Third quarter 2024 earnings released: US$1.27 loss per share (vs US$1.11 loss in 3Q 2023)

Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024

Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insufficient new directors

Chief People Strategy Officer recently sold €628k worth of stock

Second quarter 2024 earnings released: US$1.94 loss per share (vs US$1.78 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

Insufficient new directors

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insufficient new directors

Full year 2023 earnings released: US$5.34 loss per share (vs US$3.91 loss in FY 2022)

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insufficient new directors

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Third quarter 2023 earnings released: US$1.11 loss per share (vs US$1.09 loss in 3Q 2022)

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insufficient new directors

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Insufficient new directors

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold €63k worth of stock

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insufficient new directors

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Insufficient new directors

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Insufficient new directors

Insufficient new directors

Chief Operating Officer recently sold €217k worth of stock

Independent Director recently bought €805k worth of stock

Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021)

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021)

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Insmed Incorporated Names Drayton Wise as Chief Commercial Officer

Independent Director recently bought €326k worth of stock

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.89 loss in 1Q 2021)

Insmed Incorporated to Report Q1, 2022 Results on May 05, 2022

Insmed Incorporated, Annual General Meeting, May 11, 2022

Insmed Incorporated Provides Earnings Guidance for the Full Year 2022

Insmed Incorporated to Report Q4, 2021 Results on Feb 17, 2022

High number of new directors

High number of new directors

Insmed Incorporated Unable to Provides Revenue Guidance Due to Covid

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $250 million.

First quarter 2021 earnings released: US$0.89 loss per share (vs US$0.74 loss in 1Q 2020)

Independent Director recently bought €83k worth of stock

Full year 2020 earnings released: US$3.01 loss per share (vs US$3.01 loss in FY 2019)

Revenue misses expectations

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

Insmed Incorporated to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €36.40

New 90-day high: €34.20